Testing Hub

Which U.S. States Meet WHO Recommended Testing Criteria?

On May 12, 2020 the World Health Organization (WHO) advised governments that before reopening, rates of positivity in testing (ie, out of all tests conducted, how many came back positive for COVID-19) of should remain at 5% or lower for at least 14 days.

If a positivity rate is too high, that may indicate that the state is only testing the sickest patients who seek medical attention, and is not casting a wide enough net to know how much of the virus is spreading within its communities. A low rate of positivity in testing data can be seen as a sign that a state has sufficient testing capacity for the size of their outbreak and is testing enough of its population to make informed decisions about reopening. Which U.S. states are testing enough to meet the WHO’s goal?

The graph below compares states’ rate of positivity to the recommended positivity rate of 5% or below. States that meet the WHO’s recommended criteria appear in green, while the states that are not testing enough to meet the positivity benchmark are in orange.

This page was last updated on Thursday, May 28, 2020 at 11:45 PM EDT.

States that meet positivity recommendations: 23
StatePercentage of
Positive Tests
Hawaii0.02%
Montana0.10%
Alaska0.27%
Vermont0.44%
Oklahoma1.80%
Oregon1.87%
Wyoming2.01%
Nevada2.59%
Louisiana2.60%
New Mexico2.90%
States above recommended positivity: 29
StatePercentage of
Positive Tests
Puerto Rico100.00%
District of Columbia40.05%
Missouri14.85%
Georgia12.64%
Maryland11.31%
Alabama10.73%
Nebraska10.69%
Virginia10.58%
Minnesota9.19%
Iowa9.11%

This initiative relies upon publicly available data from multiple sources. States are not consistent in how and when they release and update their data, and some may even retroactively change the numbers they report. This can affect the percentages you see presented in these data visualizations. We are taking steps to account for these irregularities in how we present the information, but it is important to understand the full context behind these data.

It is important to track the testing that states are doing to diagnose people with COVID-19 infection in order to gauge the spread of COVID-19 in the U.S. and to know whether enough testing is occurring. When states report the number of COVID-19 tests performed, this should include the number of viral tests performed and the number of patients for which these tests were performed. Currently, states may not be distinguishing overall tests administered from the number of individuals who have been tested. This is an important limitation to the data that is available to track testing in the U.S., and states should work to address it.

When states report testing numbers for COVID-19 infection, they should not include serology or antibody tests. Antibody tests are not used to diagnose active COVID-19 infection and they do not provide insights into the number of cases of COVID-19 diagnosed or whether viral testing is sufficient to find infections that are occurring within each state. States that include serology tests within their overall COVID-19 testing numbers are misrepresenting their testing capacity and the extent to which they are working to identify COVID-19 infections within their communities. States that wish to track the number of serology tests being performed should report those numbers separately from viral tests performed to diagnose COVID-19.